Wired News – ObsEva Released Positive Top-line Results from IMPLANT2 Phase-3 Clinical Trial Evaluating Nolasiban in IVF

Stock Monitor: Blueprint Medicines Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 28, 2018 / Active-Investors.com has just released a free research report on ObsEva S.A. (NASDAQ: OBSV). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OBSV as the Company’s latest news hit the wire. On February 26, 2018, the clinical-stage biopharmaceutical Company announced that it has released positive top-line results of the IMPLANT2 Phase-3 clinical trial evaluating nolasiban, which is being developed for improving pregnancy rate following in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) procedures. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Blueprint Medicines Corporation (NASDAQ: BPMC), which also belongs to the Healthcare sector as the Company ObsEva. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=BPMC

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, ObsEva most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=OBSV

Follow-up data from the IMPLANT2 study will include live birth rate, and 28-day neonatal safety, expected to be reported in the fourth quarter of 2018.

IMPLANT2 Clinical Trial

IMPLANT2 is a randomized, double blind, placebo controlled clinical trial assessing nolasiban compared to placebo for improving the rate of pregnancy in patients undergoing IVF or ICSI due to low fertility. The study enrolled 778 patients from 41 fertility clinics across nine European countries. Following ovarian stimulation, egg retrieval and fertilization, prospective patients received either a single 900 mg dose of nolasiban or placebo orally on the day of embryo transfer (ET). Recruitment included patients undergoing single, fresh ET on day 3 or on day 5 after oocyte retrieval. The primary endpoint of the trial was ongoing pregnancy as determined by ultrasound at 10 weeks following ET.

Primary Endpoint of the Clinical Trial was Met

These top-line results included efficacy and safety data up to week 10 of pregnancy following embryo transfer. The primary endpoint of the clinical trial was met, with an absolute increase in ongoing pregnancy rate at 10 weeks of 7.1%, representing a relative increase of 25% in the ongoing pregnancy rate after administration of nolasiban compared to placebo. In the ET D5 subgroup, the absolute increase was 11.2% in favor of nolasiban, representing a relative increase in ongoing pregnancy rate of 32% after administration of nolasiban compared to placebo. In the ET D3 subgroup, there was a statistically non-significant 3.1% absolute increase in favor of nolasiban, or a 14% relative increase in ongoing pregnancy rate after administration of nolasiban compared to placebo. Nolasiban was well tolerated, with low rates of treatment discontinuation, and its safety profile was similar to placebo’s. No serious adverse events were reported.

Results Represent a Highly Clinically Meaningful Improvement for the Women Undergoing IVF/ICSI Procedures

Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva, stated that the Company is pleased that the IMPLANT2 results demonstrate an ongoing pregnancy benefit at 10 weeks following a single, oral dose of nolasiban, given 4 hours prior to a single ET, that not only was statistically significant, but the magnitude of which will represent a highly clinically meaningful improvement for the women undergoing IVF/ICSI procedures. Ernest added that IMPLANT2 results potentially represent one of the most important innovations in the practice of IVF/ICSI since the emergence of recombinant FSH more than 20 years ago.

About Nolasiban

Nolasiban is an oral oxytocin receptor antagonist with the potential to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. This may increase the chance of successful implantation and live-birth rates among patients undergoing ART. ObsEva licensed nolasiban from Merck-Serono in 2013 and retains worldwide, exclusive, commercial rights.

About Assisted Reproductive Technology

Assisted reproductive technology (ART) is the technology used to achieve pregnancy in procedures such as fertility medication, in vitro fertilization, and surrogacy. It is reproductive technology used primarily for infertility treatments. It mainly belongs to the field of reproductive endocrinology and infertility and may also include intracytoplasmic sperm injection (ICSI) and cryopreservation. Some forms of ART are also used with regard to fertile couples for genetic reasons. While the success of ART depends on multiple factors such as embryo quality and ET procedure, a successful pregnancy ultimately hinges on the receptivity of the uterus to accept embryo implantation.

About ObsEva S.A.

Founded in 2012 and headquartered in Switzerland, ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy.

Stock Performance Snapshot

February 27, 2018 – At Tuesday’s closing bell, ObsEva’s stock was slightly up 0.76%, ending the trading session at $14.61.

Volume traded for the day: 49.61 thousand shares, which was above the 3-month average volume of 35.63 thousand shares.

Stock performance in the last month – up 35.28%; previous three-month period – up 46.25%; past twelve-month period – up 4.43%; and year-to-date – up 49.69%

After yesterday’s close, ObsEva’s market cap was at $509.74 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 491158